ENTX today
$3.12-$0.10 (-3.11%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourLeaning Bearish
1 hourSymmetric Triangle
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $1.22
Key levels
Resistance$3.56
Resistance$3.29
Support$2.90
Support$2.66
Latest news & SEC filings
EarningsEntera Bio Posts Q3 2026 Results, Gives Business Update
EarningsEntera Bio reports Q3 EPS of $(0.11), missing $(0.07) estimate
SEC FilingEntera Bio Ltd. filed a report on a major company event (Form 8-K)
All ENTX news →About Entera Bio
Entera Bio is a clinical-stage biopharmaceutical company that develops oral tablet forms of peptide and protein therapies. Its lead candidate, EB613, is an oral parathyroid hormone tablet for postmenopausal osteoporosis, and EB612 targets hypoparathyroidism. Working with OPKO Health, the company is also developing oral peptide candidates for obesity, metabolic disorders, and short bowel syndrome. Its treatments are aimed at patients with chronic conditions who currently depend on injections.
Based on the company's 10-K filed Mar 27, 2026.
Nasdaq · Healthcare
Entera Bio Ltd. (ENTX)
What Is the Price Target for ENTX?
SEPT Low Target
$9.00
SEPT Mid Target
$9.00
SEPT High Target
$11.00
Analyst Consensus
$9.00
Is ENTX a Buy or Sell Right Now?
Thesis
- •Revenue growing -76.8% YoY with DECLINING trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ENTX.
Start Free Trial →Is ENTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$9.00
12
Moat Score
NONE
2/9
Piotroski Score
17.4
Altman Z-Score
What Is Smart Money Doing with ENTX?
Insider Signal
BUYING
5 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ENTX Growth Story
Revenue YoY
-76.8%
3yr Revenue CAGR
-58.1%
EPS Growth YoY
0%
FCF Growth YoY
-9.6%
Revenue Trend
DECLINING
Dark Pool Trades for ENTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ENTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:33:22 | $3.14 | 2,500 | $$8K | BUY |
| 15:48:28 | $3.10 | 2,250 | $$7K | SELL |
| 14:38:52 | $3.15 | 1,000 | $$3K | SELL |
| 14:30:07 | $3.27 | 2,250 | $$7K | MIDPOINT |
| 20:56:31 | $3.19 | 1,300 | $$4K | SELL |
5 dark pool trades shown · $$29K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ENTX
PREVIEWSEPT Investing provides real-time options flow tracking for ENTX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $3 | Dec 18 | 35 | $$7938 | 126 | BLOCK |
| CALL | $3 | Nov 20 | 7 | $$6678 | 126 | BLOCK |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Entera Bio Ltd. (ENTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ENTX — frequently asked questions
What is ENTX stock price today?
Entera Bio Ltd. (ENTX) is at $3.12, down 3.11% (-$0.10) at the Nov 13, 2026 close.
Why is ENTX stock moving today?
Latest ENTX news — Nov 7, 2026: Entera Bio Posts Q3 2026 Results, Gives Business Update · Nov 6, 2026: Entera Bio reports Q3 EPS of $(0.11), missing $(0.07) estimate
What is the ENTX price target?
The average analyst price target for ENTX is $9.00, ranging from $9 to $11, based on 3 analysts. Latest: Guggenheim initiates on Sep 25, 2026.
What do analysts rate ENTX?
Analyst ratings for ENTX: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did ENTX beat earnings?
ENTX last reported on Aug 7, 2026: EPS -$0.14 vs -$0.08 expected — a miss of 75.0%.
Does ENTX pay a dividend?
ENTX does not currently pay a dividend.
What are ENTX support and resistance levels?
Support: $2.90, $2.66, $2.45. Resistance: $3.29, $3.56, $4.20.
What are insiders doing with ENTX?
Insider activity: BUYING, 5 buys and 0 sells in the last 90 days.
What is the latest news on ENTX?
Nov 7, 2026: Entera Bio Posts Q3 2026 Results, Gives Business Update · Nov 6, 2026: Entera Bio reports Q3 EPS of $(0.11), missing $(0.07) estimate · Nov 6, 2026: Entera Bio Ltd. filed a report on a major company event (Form 8-K)